Marapharm is pleased to announce that it will be launching www.marapharm.tv on or before June 15, 2017.
“Marijuana is news. I did an interview on www.rightedition.com that has had in excess of 250,000 views. The success of the interview prompted us to look into the viability of doing regular media programs on the industry and on Marapharm. We have a studio, technical team and several prepared scripts. Filming is scheduled to begin May 4, 2017. Our performa indicates that millions of viewers could be reached including investors, users and those who are just interested in news of the marijuana industry. They will then also become aware of Marapharm. There will be an investor’s relation and market report of Marapharm’s stock activity at the end of each program.
In 2016 Cowen and Company, a Multi Sector Equity Research Group stated that the legal US cannabis markets to be at $6 billion (prior to California’s passage of adult use) another $25 billion is spent in the black market. The average monthly searches for “marijuana” on Google are more than 1 million per month (Source www.leafly.com April 26, 2017). These statistics were a factor when researching to create an online video channel for branding and awareness of Marapharm.” Linda Sampson, Marapharm CEO.
ABOUT MARAPHARM VENTURES INC.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol “MDM” on the Canadian Securities Exchange, and in the United States, under the ticker symbol “MRPHF” on the OTCQB, and in Europe, under the ticker symbol “2M0” on the FSE.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.